Blood transfusions guided by how you feel, not just lab numbers
NCT ID NCT07328191
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether using a simple quality-of-life questionnaire to decide when to give blood transfusions can reduce the number of transfusions needed for people with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who are receiving palliative care. Currently, transfusions are given based on hemoglobin levels, but this may not always improve how patients feel. The trial will compare the standard approach with a new one that uses weekly patient-reported well-being scores. About 52 adults will take part, and researchers will track transfusion counts, quality of life, and survival over two months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- red blood cell transfusions guided by a quality-of-life questionnaire
- What this could lead to
- If it works, this could offer a more personalized way to manage anemia in advanced blood cancers, reducing unnecessary transfusions while keeping patients comfortable.
- What could go wrong
- This is a small, early-stage study with only 52 participants. The quality-of-life approach may not reduce transfusions or could miss signs that a transfusion is needed, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 52 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 years and older. * Diagnosis of refractory MDS or AML, receiving palliative care only. * Anaemia with haemoglobin ≤ 8 g/dl at inclusion (or ≤ 9 g/dl if associated with cardiovascular disease). * Transfusion dependency, defined as requiring more than 2 GR transfusions every 8 weeks. * No vitamin B9, vitamin B12 or iron deficiency. * Ability to understand and sign the informed consent form. * Ability to comply with the schedule of visits and other protocol requirements. Non inclusion Criteria: * Previous malignant disease other than MDS or AML (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast). * Active uncontrolled infection (hepatitis B or C, HIV). * Use of G-CSF. * Confirmed neurocognitive disorders (based on prior diagnosis or clinical assessment by the investigator) impairing comprehension, consent or the ability to reliably complete the EQ-5D-5L questionnaire. * Active uncontrolled heart disease. * Active haemolytic anaemia. * Recent major surgery. * Life-threatening complications of MDS/AML. * Presence of another serious or unstable disease which, in the investigators' opinion, would make participation in the study inappropriate or risky for the patient's safety. * Vulnerable individuals. Exclusion Criteria: * Immediate severe complications related to MDS/AML, such as uncontrolled bleeding, pneumonia with hypoxia or shock, or severe disseminated intravascular coagulopathy. * Withdrawal of the patient's voluntary informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, adult are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Nice
RECRUITINGNice, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gentler transplant prep aims to cure tough blood cancers
- Can IV iron boost blood levels and daily energy for mothers before and after delivery?
- Can a liposomal chemo combo improve outcomes before stem cell transplant?
- Iron boost before heart surgery may cut need for donor blood
- Can scheduled malaria drugs shield infants from severe illness?
- Can a simple preventive drug cut malaria and anemia in infants?